Accurdx, a high-tech firm specializing in IVD instruments and supporting reagents, will continue to focus on technological innovation and independent R&D construction with the fresh proceeds.
Accurdx (Chinese: 艾科达), a provider of in vitro diagnostic instruments and reagents, announced its completion of the Series A financing round worth more than CNY 100 million. The round was invested conjointly by Addor Capital (Chinese: 毅达资本) and CITIC Medical Fund (Chinese: 中信医疗基金). Sterling Capital (Chinese: 锐翎资本) served as the exclusive financial advisor for this round.
The funds will be used to help the company continue to focus on the field of coagulation and the R&D production of reagent raw materials. The company will also use the funds to improve production scale, R&D results transformation and high-level talent team building.
Founded in 2017, Accurdx is an innovative enterprise with hemostasis and thrombosis detection as the core technology, integrating raw materials, diagnostic reagents, diagnostic instruments, automated assembly line development, production, sales and technical services. The company's products cover coagulation testing systems, immunoassay systems, specific protein testing systems and reproductive testing systems. It provides clinical laboratory automation solutions for bleeding and hemostasis, cardiovascular diseases and colorectal cancer screening.
Since its establishment, Accurdx has obtained 45 production licenses, 10 registration for fully automated analyzers, 35 reagent registrations and 83 patents for inventions and other items.
The company's competitors include BSBE (Chinese: 九强生物), Sinnowa (Chinese: 英诺华) and Rayto (Chinese: 深圳雷杜).